At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 50 enrolled
Drug / intervention
Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Evaluate the Safety and Immunogenicity of an Ad26.ZEBOV Booster Dose in Children Previously Vaccinated With the Ad26.ZEBOV and MVA-BN-Filo Vaccine Regimen
London School of Hygiene and Tropical Medicine·interventional·Posted Jan 15, 2021·Updated Dec 13, 2023
In Brief
A Phase 2 clinical trial evaluating Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection for Ebola Virus Disease. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEbola Virus Disease
CountriesSierra Leone
CollaboratorsInnovative Medicines Initiative, University of Sierra Leone
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJul 2021
Primary CompletionSep 2021
Study CompletionMar 2022
TodayJul 2026
First PostedJan 15, 2021
Enrollment StartJul 8, 2021
Primary CompletionSep 17, 2021
Study CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.5 years ago
Interventions
Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injectiondrug
Ad26.ZEBOV is a monovalent, replication-incompetent adenovirus serotype 26-based vector that expresses the full-length Ebola virus Mayinga glycoprotein